Immunoscore Signatures in Surgical Specimens and Tumor-Infiltrating Lymphocytes in Pretreatment Biopsy Predict Treatment Efficacy and Survival in Esophageal Cancer
Tumor-infiltrating lymphocytes (TILs) have long been recognized as playing an important role in tumor immune microenvironment. Lately, the Immunoscore (IS) has been proposed as a new method of quantifying the number of TILs in association with patient survival in several cancer types. In 300 preoper...
Gespeichert in:
Veröffentlicht in: | Annals of surgery 2023-03, Vol.277 (3), p.e528-e537 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | e537 |
---|---|
container_issue | 3 |
container_start_page | e528 |
container_title | Annals of surgery |
container_volume | 277 |
creator | Noma, Toshiki Makino, Tomoki Ohshima, Kenji Sugimura, Keijiro Miyata, Hiroshi Honma, Keiichiro Yamashita, Kotaro Saito, Takuro Tanaka, Koji Yamamoto, Kazuyoshi Takahashi, Tsuyoshi Kurokawa, Yukinori Yamasaki, Makoto Nakajima, Kiyokazu Morii, Eiichi Eguchi, Hidetoshi Doki, Yuichiro |
description | Tumor-infiltrating lymphocytes (TILs) have long been recognized as playing an important role in tumor immune microenvironment. Lately, the Immunoscore (IS) has been proposed as a new method of quantifying the number of TILs in association with patient survival in several cancer types.
In 300 preoperatively untreated esophageal cancer (EC) patients who underwent curative resection at two different institutes, immunohistochemical staining using CD3 and CD8 antibodies was performed to evaluate IS, as objectively scored by auto-counted TILs in the tumor core and invasive margin. In addition, in pre-neoadjuvant chemotherapy (pre-NAC) endoscopic biopsies of a different cohort of 146 EC patients who received NAC, CD3, and CD8 were immunostained to evaluate TIL density.
In all cases, the IS-high (score 3-4) group tended to have better survival [5-year overall survival (OS) of the IS-high vs low group: 77.6 vs 65.8%, P = 0.0722] than the IS-low (score 1-2) group. This trend was more remarkable in cStage II-IV patients (70.2 vs 54.5%, P = 0.0208) and multivariate analysis of OS further identified IS (hazard ratio 2.07, P = 0.0043) to be an independent prognostic variable. In preNAC biopsies, NAC-responders had higher densities than non-responders of both CD3 + ( P = 0.0106) and CD8 + cells ( P = 0.0729) and, particularly CD3 + cell density was found to be an independent prognostic factor (hazard ratio 1.75, P = 0.0169).
The IS signature in surgical specimens and TIL density in preNAC- biopsies could be predictive markers of clinical outcomes in EC patients. |
doi_str_mv | 10.1097/SLA.0000000000005104 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10060045</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2557536410</sourcerecordid><originalsourceid>FETCH-LOGICAL-c6042-50edae6ea41eb30a4262531a10cd5b8d61b124e119020a14dca04e4ba7d286cb3</originalsourceid><addsrcrecordid>eNpdkcGO0zAQhiMEYsvCGyCUI5fsjmM7TU9oqQpUqgRSy9lynEliSOxgO13leXhRvHS3u-CL5Zn5v3_kP0neErgisFpe73c3V_DkcALsWbIgPC8zQhg8TxaxSjO2ovlF8sr7HwCElbB8mVxQRikrOFkkv7fDMBnrlXWY7nVrZJgc-lSbdD-5VivZp_sRlR7Q-FSaOj1Mg3XZ1jS6D04Gbdp0Nw9jZ9UcTsJvDoNDGaIkpB-1Hf18V6u1Cunh3Ng0TaSr-S80eh31MXpF-cbbsZMtxtdaGoXudfKikb3HN_f3ZfL90-aw_pLtvn7erm92mSqA5RkHrCUWKBnBioJkeZFzSiQBVfOqrAtSkZwhISvIQRJWKwkMWSWXdV4WqqKXyYcTd5yqAWsVt3SyF6PTg3SzsFKLfztGd6K1R0EACgDGI-H9PcHZXxP6IAbtFfa9NGgnL3LOl5wWjEAcZadR5az3DpuzDwFxF7CIAYv_A46yd093PIseEn3k3to-oPM_--kWnejid4buxCt4ma0eqNmK0jKnfwAES7VA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2557536410</pqid></control><display><type>article</type><title>Immunoscore Signatures in Surgical Specimens and Tumor-Infiltrating Lymphocytes in Pretreatment Biopsy Predict Treatment Efficacy and Survival in Esophageal Cancer</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><source>PubMed Central</source><creator>Noma, Toshiki ; Makino, Tomoki ; Ohshima, Kenji ; Sugimura, Keijiro ; Miyata, Hiroshi ; Honma, Keiichiro ; Yamashita, Kotaro ; Saito, Takuro ; Tanaka, Koji ; Yamamoto, Kazuyoshi ; Takahashi, Tsuyoshi ; Kurokawa, Yukinori ; Yamasaki, Makoto ; Nakajima, Kiyokazu ; Morii, Eiichi ; Eguchi, Hidetoshi ; Doki, Yuichiro</creator><creatorcontrib>Noma, Toshiki ; Makino, Tomoki ; Ohshima, Kenji ; Sugimura, Keijiro ; Miyata, Hiroshi ; Honma, Keiichiro ; Yamashita, Kotaro ; Saito, Takuro ; Tanaka, Koji ; Yamamoto, Kazuyoshi ; Takahashi, Tsuyoshi ; Kurokawa, Yukinori ; Yamasaki, Makoto ; Nakajima, Kiyokazu ; Morii, Eiichi ; Eguchi, Hidetoshi ; Doki, Yuichiro</creatorcontrib><description>Tumor-infiltrating lymphocytes (TILs) have long been recognized as playing an important role in tumor immune microenvironment. Lately, the Immunoscore (IS) has been proposed as a new method of quantifying the number of TILs in association with patient survival in several cancer types.
In 300 preoperatively untreated esophageal cancer (EC) patients who underwent curative resection at two different institutes, immunohistochemical staining using CD3 and CD8 antibodies was performed to evaluate IS, as objectively scored by auto-counted TILs in the tumor core and invasive margin. In addition, in pre-neoadjuvant chemotherapy (pre-NAC) endoscopic biopsies of a different cohort of 146 EC patients who received NAC, CD3, and CD8 were immunostained to evaluate TIL density.
In all cases, the IS-high (score 3-4) group tended to have better survival [5-year overall survival (OS) of the IS-high vs low group: 77.6 vs 65.8%, P = 0.0722] than the IS-low (score 1-2) group. This trend was more remarkable in cStage II-IV patients (70.2 vs 54.5%, P = 0.0208) and multivariate analysis of OS further identified IS (hazard ratio 2.07, P = 0.0043) to be an independent prognostic variable. In preNAC biopsies, NAC-responders had higher densities than non-responders of both CD3 + ( P = 0.0106) and CD8 + cells ( P = 0.0729) and, particularly CD3 + cell density was found to be an independent prognostic factor (hazard ratio 1.75, P = 0.0169).
The IS signature in surgical specimens and TIL density in preNAC- biopsies could be predictive markers of clinical outcomes in EC patients.</description><identifier>ISSN: 0003-4932</identifier><identifier>EISSN: 1528-1140</identifier><identifier>DOI: 10.1097/SLA.0000000000005104</identifier><identifier>PMID: 34334651</identifier><language>eng</language><publisher>United States: Wolters Kluwer Health, Inc. All rights reserved</publisher><subject>Biopsy ; Esophageal Neoplasms - pathology ; Esophageal Neoplasms - surgery ; Humans ; Lymphocytes, Tumor-Infiltrating ; Original ; Prognosis ; Treatment Outcome ; Tumor Microenvironment</subject><ispartof>Annals of surgery, 2023-03, Vol.277 (3), p.e528-e537</ispartof><rights>Wolters Kluwer Health, Inc. All rights reserved.</rights><rights>Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.</rights><rights>Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c6042-50edae6ea41eb30a4262531a10cd5b8d61b124e119020a14dca04e4ba7d286cb3</citedby><cites>FETCH-LOGICAL-c6042-50edae6ea41eb30a4262531a10cd5b8d61b124e119020a14dca04e4ba7d286cb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060045/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060045/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34334651$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Noma, Toshiki</creatorcontrib><creatorcontrib>Makino, Tomoki</creatorcontrib><creatorcontrib>Ohshima, Kenji</creatorcontrib><creatorcontrib>Sugimura, Keijiro</creatorcontrib><creatorcontrib>Miyata, Hiroshi</creatorcontrib><creatorcontrib>Honma, Keiichiro</creatorcontrib><creatorcontrib>Yamashita, Kotaro</creatorcontrib><creatorcontrib>Saito, Takuro</creatorcontrib><creatorcontrib>Tanaka, Koji</creatorcontrib><creatorcontrib>Yamamoto, Kazuyoshi</creatorcontrib><creatorcontrib>Takahashi, Tsuyoshi</creatorcontrib><creatorcontrib>Kurokawa, Yukinori</creatorcontrib><creatorcontrib>Yamasaki, Makoto</creatorcontrib><creatorcontrib>Nakajima, Kiyokazu</creatorcontrib><creatorcontrib>Morii, Eiichi</creatorcontrib><creatorcontrib>Eguchi, Hidetoshi</creatorcontrib><creatorcontrib>Doki, Yuichiro</creatorcontrib><title>Immunoscore Signatures in Surgical Specimens and Tumor-Infiltrating Lymphocytes in Pretreatment Biopsy Predict Treatment Efficacy and Survival in Esophageal Cancer</title><title>Annals of surgery</title><addtitle>Ann Surg</addtitle><description>Tumor-infiltrating lymphocytes (TILs) have long been recognized as playing an important role in tumor immune microenvironment. Lately, the Immunoscore (IS) has been proposed as a new method of quantifying the number of TILs in association with patient survival in several cancer types.
In 300 preoperatively untreated esophageal cancer (EC) patients who underwent curative resection at two different institutes, immunohistochemical staining using CD3 and CD8 antibodies was performed to evaluate IS, as objectively scored by auto-counted TILs in the tumor core and invasive margin. In addition, in pre-neoadjuvant chemotherapy (pre-NAC) endoscopic biopsies of a different cohort of 146 EC patients who received NAC, CD3, and CD8 were immunostained to evaluate TIL density.
In all cases, the IS-high (score 3-4) group tended to have better survival [5-year overall survival (OS) of the IS-high vs low group: 77.6 vs 65.8%, P = 0.0722] than the IS-low (score 1-2) group. This trend was more remarkable in cStage II-IV patients (70.2 vs 54.5%, P = 0.0208) and multivariate analysis of OS further identified IS (hazard ratio 2.07, P = 0.0043) to be an independent prognostic variable. In preNAC biopsies, NAC-responders had higher densities than non-responders of both CD3 + ( P = 0.0106) and CD8 + cells ( P = 0.0729) and, particularly CD3 + cell density was found to be an independent prognostic factor (hazard ratio 1.75, P = 0.0169).
The IS signature in surgical specimens and TIL density in preNAC- biopsies could be predictive markers of clinical outcomes in EC patients.</description><subject>Biopsy</subject><subject>Esophageal Neoplasms - pathology</subject><subject>Esophageal Neoplasms - surgery</subject><subject>Humans</subject><subject>Lymphocytes, Tumor-Infiltrating</subject><subject>Original</subject><subject>Prognosis</subject><subject>Treatment Outcome</subject><subject>Tumor Microenvironment</subject><issn>0003-4932</issn><issn>1528-1140</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkcGO0zAQhiMEYsvCGyCUI5fsjmM7TU9oqQpUqgRSy9lynEliSOxgO13leXhRvHS3u-CL5Zn5v3_kP0neErgisFpe73c3V_DkcALsWbIgPC8zQhg8TxaxSjO2ovlF8sr7HwCElbB8mVxQRikrOFkkv7fDMBnrlXWY7nVrZJgc-lSbdD-5VivZp_sRlR7Q-FSaOj1Mg3XZ1jS6D04Gbdp0Nw9jZ9UcTsJvDoNDGaIkpB-1Hf18V6u1Cunh3Ng0TaSr-S80eh31MXpF-cbbsZMtxtdaGoXudfKikb3HN_f3ZfL90-aw_pLtvn7erm92mSqA5RkHrCUWKBnBioJkeZFzSiQBVfOqrAtSkZwhISvIQRJWKwkMWSWXdV4WqqKXyYcTd5yqAWsVt3SyF6PTg3SzsFKLfztGd6K1R0EACgDGI-H9PcHZXxP6IAbtFfa9NGgnL3LOl5wWjEAcZadR5az3DpuzDwFxF7CIAYv_A46yd093PIseEn3k3to-oPM_--kWnejid4buxCt4ma0eqNmK0jKnfwAES7VA</recordid><startdate>20230301</startdate><enddate>20230301</enddate><creator>Noma, Toshiki</creator><creator>Makino, Tomoki</creator><creator>Ohshima, Kenji</creator><creator>Sugimura, Keijiro</creator><creator>Miyata, Hiroshi</creator><creator>Honma, Keiichiro</creator><creator>Yamashita, Kotaro</creator><creator>Saito, Takuro</creator><creator>Tanaka, Koji</creator><creator>Yamamoto, Kazuyoshi</creator><creator>Takahashi, Tsuyoshi</creator><creator>Kurokawa, Yukinori</creator><creator>Yamasaki, Makoto</creator><creator>Nakajima, Kiyokazu</creator><creator>Morii, Eiichi</creator><creator>Eguchi, Hidetoshi</creator><creator>Doki, Yuichiro</creator><general>Wolters Kluwer Health, Inc. All rights reserved</general><general>Lippincott Williams & Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230301</creationdate><title>Immunoscore Signatures in Surgical Specimens and Tumor-Infiltrating Lymphocytes in Pretreatment Biopsy Predict Treatment Efficacy and Survival in Esophageal Cancer</title><author>Noma, Toshiki ; Makino, Tomoki ; Ohshima, Kenji ; Sugimura, Keijiro ; Miyata, Hiroshi ; Honma, Keiichiro ; Yamashita, Kotaro ; Saito, Takuro ; Tanaka, Koji ; Yamamoto, Kazuyoshi ; Takahashi, Tsuyoshi ; Kurokawa, Yukinori ; Yamasaki, Makoto ; Nakajima, Kiyokazu ; Morii, Eiichi ; Eguchi, Hidetoshi ; Doki, Yuichiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c6042-50edae6ea41eb30a4262531a10cd5b8d61b124e119020a14dca04e4ba7d286cb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Biopsy</topic><topic>Esophageal Neoplasms - pathology</topic><topic>Esophageal Neoplasms - surgery</topic><topic>Humans</topic><topic>Lymphocytes, Tumor-Infiltrating</topic><topic>Original</topic><topic>Prognosis</topic><topic>Treatment Outcome</topic><topic>Tumor Microenvironment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Noma, Toshiki</creatorcontrib><creatorcontrib>Makino, Tomoki</creatorcontrib><creatorcontrib>Ohshima, Kenji</creatorcontrib><creatorcontrib>Sugimura, Keijiro</creatorcontrib><creatorcontrib>Miyata, Hiroshi</creatorcontrib><creatorcontrib>Honma, Keiichiro</creatorcontrib><creatorcontrib>Yamashita, Kotaro</creatorcontrib><creatorcontrib>Saito, Takuro</creatorcontrib><creatorcontrib>Tanaka, Koji</creatorcontrib><creatorcontrib>Yamamoto, Kazuyoshi</creatorcontrib><creatorcontrib>Takahashi, Tsuyoshi</creatorcontrib><creatorcontrib>Kurokawa, Yukinori</creatorcontrib><creatorcontrib>Yamasaki, Makoto</creatorcontrib><creatorcontrib>Nakajima, Kiyokazu</creatorcontrib><creatorcontrib>Morii, Eiichi</creatorcontrib><creatorcontrib>Eguchi, Hidetoshi</creatorcontrib><creatorcontrib>Doki, Yuichiro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Noma, Toshiki</au><au>Makino, Tomoki</au><au>Ohshima, Kenji</au><au>Sugimura, Keijiro</au><au>Miyata, Hiroshi</au><au>Honma, Keiichiro</au><au>Yamashita, Kotaro</au><au>Saito, Takuro</au><au>Tanaka, Koji</au><au>Yamamoto, Kazuyoshi</au><au>Takahashi, Tsuyoshi</au><au>Kurokawa, Yukinori</au><au>Yamasaki, Makoto</au><au>Nakajima, Kiyokazu</au><au>Morii, Eiichi</au><au>Eguchi, Hidetoshi</au><au>Doki, Yuichiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunoscore Signatures in Surgical Specimens and Tumor-Infiltrating Lymphocytes in Pretreatment Biopsy Predict Treatment Efficacy and Survival in Esophageal Cancer</atitle><jtitle>Annals of surgery</jtitle><addtitle>Ann Surg</addtitle><date>2023-03-01</date><risdate>2023</risdate><volume>277</volume><issue>3</issue><spage>e528</spage><epage>e537</epage><pages>e528-e537</pages><issn>0003-4932</issn><eissn>1528-1140</eissn><abstract>Tumor-infiltrating lymphocytes (TILs) have long been recognized as playing an important role in tumor immune microenvironment. Lately, the Immunoscore (IS) has been proposed as a new method of quantifying the number of TILs in association with patient survival in several cancer types.
In 300 preoperatively untreated esophageal cancer (EC) patients who underwent curative resection at two different institutes, immunohistochemical staining using CD3 and CD8 antibodies was performed to evaluate IS, as objectively scored by auto-counted TILs in the tumor core and invasive margin. In addition, in pre-neoadjuvant chemotherapy (pre-NAC) endoscopic biopsies of a different cohort of 146 EC patients who received NAC, CD3, and CD8 were immunostained to evaluate TIL density.
In all cases, the IS-high (score 3-4) group tended to have better survival [5-year overall survival (OS) of the IS-high vs low group: 77.6 vs 65.8%, P = 0.0722] than the IS-low (score 1-2) group. This trend was more remarkable in cStage II-IV patients (70.2 vs 54.5%, P = 0.0208) and multivariate analysis of OS further identified IS (hazard ratio 2.07, P = 0.0043) to be an independent prognostic variable. In preNAC biopsies, NAC-responders had higher densities than non-responders of both CD3 + ( P = 0.0106) and CD8 + cells ( P = 0.0729) and, particularly CD3 + cell density was found to be an independent prognostic factor (hazard ratio 1.75, P = 0.0169).
The IS signature in surgical specimens and TIL density in preNAC- biopsies could be predictive markers of clinical outcomes in EC patients.</abstract><cop>United States</cop><pub>Wolters Kluwer Health, Inc. All rights reserved</pub><pmid>34334651</pmid><doi>10.1097/SLA.0000000000005104</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0003-4932 |
ispartof | Annals of surgery, 2023-03, Vol.277 (3), p.e528-e537 |
issn | 0003-4932 1528-1140 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10060045 |
source | MEDLINE; Journals@Ovid Complete; PubMed Central |
subjects | Biopsy Esophageal Neoplasms - pathology Esophageal Neoplasms - surgery Humans Lymphocytes, Tumor-Infiltrating Original Prognosis Treatment Outcome Tumor Microenvironment |
title | Immunoscore Signatures in Surgical Specimens and Tumor-Infiltrating Lymphocytes in Pretreatment Biopsy Predict Treatment Efficacy and Survival in Esophageal Cancer |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T02%3A31%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunoscore%20Signatures%20in%20Surgical%20Specimens%20and%20Tumor-Infiltrating%20Lymphocytes%20in%20Pretreatment%20Biopsy%20Predict%20Treatment%20Efficacy%20and%20Survival%20in%20Esophageal%20Cancer&rft.jtitle=Annals%20of%20surgery&rft.au=Noma,%20Toshiki&rft.date=2023-03-01&rft.volume=277&rft.issue=3&rft.spage=e528&rft.epage=e537&rft.pages=e528-e537&rft.issn=0003-4932&rft.eissn=1528-1140&rft_id=info:doi/10.1097/SLA.0000000000005104&rft_dat=%3Cproquest_pubme%3E2557536410%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2557536410&rft_id=info:pmid/34334651&rfr_iscdi=true |